- |||||||||| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Humira (adalimumab) / AbbVie
Biomarker, Journal: Transcriptomic Identification of Immune-Related Hubs as Candidate Predictor Biomarkers of Therapeutic Response in Psoriasis. (Pubmed Central) - Sep 13, 2025
Similarly, skin expression of CXCL8, IL-6, and CXCL10, alongside plasma levels of CCL20, IL-6, and CXCL8, may predict anti-IL-23 response. Ten immune-related hubs may serve as possible biomarkers for disease severity and therapeutic response in psoriasis.
- |||||||||| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Tremfya (guselkumab) / J&J
Retrospective Non-Interventional Chart Review of Guselkumab and Risankizumab in Swedish Patients with Plaque Psoriasis () - Sep 12, 2025 - Abstract #ESDR2025ESDR_572;
Most patients (92.4 %), %) had previously received biologic therapy, with adalimumab being the most used agent (49.4 %)...Differences in baseline characteristics between treatment groups were observed, with guselkumab-treated patients more frequently having psoriatic arthritis than risankizumab-treated patients (26.6% vs. 19.4%). This study presents real-world data on the baseline characteristics of Swedish patients with plaque psoriasis treated with guselkumab or risankizumab, thereby contributing to a deeper understanding of the clinical profiles of these patient populations.
- |||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Humira (adalimumab) / AbbVie
A PASH-Like Autoinflammatory Syndrom in an Adult Female () - Sep 12, 2025 - Abstract #ESDR2025ESDR_700;
She used amoxicillin-clavulanate long-term with partial improvement...Adalimumab (80 mg biweekly) was initiated, and isotretinoin tapered...While resembling PASH, the absence of arthritis excludes PAPASH. The clinical course supports a broader, yet unclassified, autoinflammatory condition involving inflammasome activity and TNF/IL-23-driven inflammation.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Journal: Evaluation of point-of-care instrument for quantification of infliximab and adalimumab. (Pubmed Central) - Sep 12, 2025
We find the efficacy and accuracy of the ProciseDx acceptable, but when performed by non-laboratory personnel, the differences to routine measurements are considerable and could have a clinical impact. Clinical implementation would at least require reevaluation of the therapeutic intervals.
- |||||||||| Simponi (golimumab) / J&J, Humira (adalimumab) / AbbVie
Journal: Evaluation of the performance of biological drugs in the treatment of ankylosing spondylitis: cohort study, Minas Gerais, 2018-2023. (Pubmed Central) - Sep 10, 2025
The analysis of persistence and time to discontinuation showed no differences between the drugs, which justified their maintenance in the first line of treatment of the protocol. Factors associated with the clinical profile of users may be related to differences in effectiveness, but more in-depth studies are needed to confirm these results, given the limitations of using administrative data in epidemiological research.
- |||||||||| Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Journal: Risk of Ophthalmologic Comorbidities in Hidradenitis Suppurativa Patients. (Pubmed Central) - Sep 4, 2025
This study found an increased risk for corneal ulcers, marginal corneal ulcers, and scleritis in adults with HS. Use of biologics was associated with a reduced risk of conjunctivitis in patients with HS compared to patients who did not have biologic exposure.
- |||||||||| Review, Journal, Real-world evidence: Literature analysis and implication of biologic therapy for children with non-systemic juvenile idiopathic arthritis in real-world settings. (Pubmed Central) - Sep 4, 2025
Adalimumab, etanercept and tocilizumab have comparable effectiveness for treating polyJIA, and these drugs are also well-tolerated...The use of TNFi did not seem to significantly increase this risk further when compared to using methotrexate...The reimbursement policy and pricing issue of bDMARDs are out of the scope of the present literature analysis. The current review may help inform shared decision-making discussions between families and physicians as they weigh the risks and benefits of various treatment approaches for children with JIA.
- |||||||||| mycophenolate mofetil / Generic mfg., Humira (adalimumab) / AbbVie
Journal: Secondary amyloidosis as a cause of nephrotic syndrome in Takayasu arteritis. (Pubmed Central) - Sep 4, 2025
At 6 months she underwent transfemoral coronary, pulmonary, peripheral angiogram and percutaneous transluminal angioplasty (PTA) with stenting of left subclavian and left renal artery.In patients with inadequately treated TA and nephrotic range proteinuria, renal AA amyloidosis is not an uncommon diagnosis. Systemic amyloidosis is an adverse prognostic sign in TA, and it is imperative to have a high index of suspicion.
- |||||||||| Journal, Adverse events: Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events. (Pubmed Central) - Sep 4, 2025
inhibitors (adalimumab or etanercept) for similar indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active comparator...In this case-time-control study based on a national insurance database, there was no evidence of a significant association between MACEs and the initiation of IL-17(R)A inhibitors, regardless of the individual cardiovascular risk of the patient. However, a modest risk increase cannot be entirely excluded.
- |||||||||| Humira (adalimumab) / AbbVie
Clinical, Retrospective data, Journal, HEOR: Instrumental variable approaches for estimating time-varying treatment effects in comparative effectiveness research. (Pubmed Central) - Sep 4, 2025
The proposed IV-based g-estimation approach can be reliably used in the estimation of time-varying treatments if a valid time-varying IV is available. The weighting approach offers an accessible alternative but was found to work well only when the IVs are strongly associated with treatment assignment, which is relatively unlikely in real-world applications.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Implementation of inline Raman spectroscopy for buffer exchange monitoring in monoclonal antibody formulation. (Pubmed Central) - Sep 4, 2025
This study aimed to evaluate the application of inline Raman spectroscopy for real-time monitoring of excipients-specifically sucrose, histidine, mannitol, and hydroxypropyl-?-cyclodextrin (HP?CD)-during the buffer exchange process of adalimumab-based formulations...In summary, Raman spectroscopy, when combined with validated chemometric models, enables the real-time quantification of multiple excipients during buffer exchange. This approach offers a fast, non-destructive and cost-effective alternative to HPLC, enhancing process control, manufacturing efficiency, and product quality in continuous biomanufacturing.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Retrospective data, Journal: Predictors of anti-TNF treatment failure in intestinal Beh (Pubmed Central) - Aug 29, 2025
Our model can identify high-risk patients early, allowing for the timely optimization of treatment regimens. Key Points
- |||||||||| Bimzelx (bimekizumab-bkzx) / UCB, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Journal: Hidradenitis suppurativa: state-of-the-art review and update. (Pubmed Central) - Aug 28, 2025
Effective management focuses on early intervention to prevent irreversible damage, control symptoms such as pain, and address systemic comorbidities. A timely diagnosis, along with a multidisciplinary and personalized approach, is essential for improving patient outcomes and quality of life.
- |||||||||| methotrexate / Generic mfg., Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie
Journal: Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. (Pubmed Central) - Aug 28, 2025
P2, P2/3,
This descriptive analysis indicates a long-term safety profile of upadacitinib consistent with previous reports, further supporting long-term treatment of chronic diseases with upadacitinib. Variations in TEAE rates across indications likely reflected differences in populations and underlying comorbidities.
- |||||||||| Kineret (anakinra) / SOBI, Humira (adalimumab) / AbbVie
Evidence-based Individual Treatment Trials Using Immunomodulators in Neuropathic and Non-neuronopathic Patients with Mucopolysaccharidosis (Poster 1 Annex Hall) - Aug 28, 2025 - Abstract #ICIEM2025ICIEM_1506;
Variations in TEAE rates across indications likely reflected differences in populations and underlying comorbidities. Based on the DAF tool, the TNF-alpha inhibitor adalimumab (20 mg, s.c, biweekly) was selected as the first-line treatment for a 30-year-old MPS IV A patient...Three MPS III patients (two type A, with 5 and 10 years of age, and one type B, with 11 years of age) were treated with anakinra, an IL-1 receptor antagonist...Ongoing feedback from physicians, patients and parents will enhance the DAF tools
- |||||||||| Kineret (anakinra) / SOBI, Humira (adalimumab) / AbbVie
Evidence-based Individual Treatment Trials Using Immunomodulators in Neuropathic and Non-neuronopathic Patients with Mucopolysaccharidosis (Poster 1 Annex Hall) - Aug 28, 2025 - Abstract #ICIEM2025ICIEM_838;
Based on the DAF tool, the TNF-alpha inhibitor adalimumab (20 mg, s.c, biweekly) was selected as the first-line treatment for a 30-year-old MPS IV A patient...Three MPS III patients (two type A, with 5 and 10 years of age, and one type B, with 11 years of age) were treated with anakinra, an IL-1 receptor antagonist...Ongoing feedback from physicians, patients and parents will enhance the DAF tools Based on the DAF tool, the TNF-alpha inhibitor adalimumab (20 mg, s.c, biweekly) was selected as the first-line treatment for a 30-year-old MPS IV A patient...Three MPS III patients (two type A, with 5 and 10 years of age, and one type B, with 11 years of age) were treated with anakinra, an IL-1 receptor antagonist...Ongoing feedback from physicians, patients and parents will enhance the DAF tools
- |||||||||| methotrexate / Generic mfg., risedronate / Generic mfg., Humira (adalimumab) / AbbVie
Journal: Eruptive acral syringomas: A case report and review of literature. (Pubmed Central) - Aug 28, 2025
Treatment is challenging due to their dermal depth and recurrence risk, with lasers and retinoids among the options. This case highlights the diagnostic complexity of acral eruptive syringomas.
- |||||||||| Humira (adalimumab) / AbbVie
Journal, Adverse events, IO biomarker: Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors. (Pubmed Central) - Aug 27, 2025
It was found that interleukin-17 inhibitors induced an anti-inflammatory state and potentially more active toll-like receptor 3-mediated antiviral responses compared with adalimumab. In conclusion, screening for oral Candida albicans colonization prior to initiation of interleukin-17 inhibitor therapy may be a useful strategy for risk stratification and early intervention.
- |||||||||| Humira (adalimumab) / AbbVie
Clinical, Review, Journal: Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis. (Pubmed Central) - Aug 26, 2025
These agents can be ingested orally and seem superior to adalimumab for most indications...In the absence of evidence from controlled clinical trials, JAK inhibitor therapy is still rendered experimental and currently considered only for sight-threatening uveitis. JAK inhibitors may be considered for specific NIU entities for which there is insufficient response or secondary loss of response to conventional or biologic disease-modifying drugs.
- |||||||||| Humira (adalimumab) / AbbVie
Journal: Clinical and Imaging Characteristics of Posterior Scleritis in Children. (Pubmed Central) - Aug 26, 2025
Adalimumab was added in 2 patients...B-scan ultrasound remains the gold standard test. OCT proved to be of practical importance in delineating the magnitude of RNFL thickness and could serve as a potential imaging biomarker of disease activity.
- |||||||||| Humira (adalimumab) / AbbVie
Journal, HEOR, Cost-effectiveness: Economic Burden and Cost-Effectiveness of Management of Non-Infectious Uveitis: A Systematic Review. (Pubmed Central) - Aug 26, 2025
Overall, cost-effectiveness analyses show promise for treatments like adalimumab and certain implants, though the extent of economic benefit depends on price reductions and healthcare system variations...NIU poses a significant economic impact, particularly in patients with blindness and those on advanced therapies. While evidence is growing in Western countries like the US and UK, further research in non-westernized countries is warranted for a comprehensive, global understanding of the disease's economic burden.
- |||||||||| Review, Journal: Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review. (Pubmed Central) - Aug 26, 2025
In the case of contraindications or treatment failure of traditional systemic therapies, among biologic drugs, the rapidity of action, safety, and limited evidence of efficacy are in favor of IL-17 inhibitors and risankizumab. However, the findings we report are limited by the evidence available in current literature, which is characterized by low statistical power.
- |||||||||| Journal, HEOR, Cost-effectiveness: Aggregate Distributional Cost-Effectiveness Analysis of Biologics for the Treatment of Ankylosing Spondylitis in Chile. (Pubmed Central) - Aug 26, 2025
Biologic treatment for ankylosing spondylitis, such as secukinumab, may reduce health inequity in the Chilean population. An aggregate distributional cost-effectiveness analysis framework is feasible to implement alongside a cost-effectiveness analysis in the context of the Chilean healthcare system to provide additional information of equity impacts for health technology assessment recommendations and policy making.
|
